Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1998467 | Molecular Genetics and Metabolism | 2011 | 4 Pages |
Abstract
The shortage of enzyme for treatment of Fabry disease has caused anxiety among patients, physicians and governments. Following a request from the European Medicines Agency, consensus was reached on the temporary prioritization of patients for treatment based on disease severity and potential reversibility. Advice on follow-up of patients was agreed upon. This consensus is proposed to support the temporary guidelines issued throughout the period of ERT shortage, which will most likely last until April 2011.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Gabor E. Linthorst, Dominique P. Germain, Carla E.M. Hollak, Derralynn Hughes, Arndt Rolfs, Christoph Wanner, Atul Mehta,